BSE · 543346
Aashka Hospitals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹26 Cr with net profit ₹3 Cr — a 12.57% net margin, versus 8.7% the period before.
Shareholding
As of 2026-03-31
- Promoter61.33%
- Public38.67%
1,126 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.69× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,25,042 Cr | 59.43 | 13.21 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹99,764 Cr | 66.64 | 9.35 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹93,997 Cr | 100.22 | 5.72 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹65,704 Cr | 61.59 | 6.63 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹64,504 Cr | 166.29 | 15.35 | 8.48% | 6.54% |
| Narayana Hrudayalaya Ltd. | ₹37,839 Cr | 43.9 | 8.34 | 17.76% | 9% |
| Global Health Limited | ₹37,766 Cr | 65.97 | 9.54 | 14.05% | 11.88% |
| Krishna Institute of Medical Sciences Ltd. | ₹32,200 Cr | 154.26 | 8.6 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹31,819 Cr | 56.57 | 12.67 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,239 Cr | 53.87 | 5.57 | 10.37% | 15.77% |
| Aashka Hospitals Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAashka Hospitals Limited, with a market capitalization of Rs 276 Cr, reported revenue of Rs 25.99 Cr. The company's 52-week high share price was Rs 103, and its 52-week low was Rs 59.
Positives
- +The debt-to-equity ratio is 0.17, indicating relatively low financial leverage.
- +Promoter holding of 61.33% as of Mar 2026 suggests significant owner commitment.
- +Net profit rebounded to Rs 3.27 Cr in Mar 2025 after a loss in Mar 2023.
Negatives
- −Revenue has seen a decline from Rs 40.69 Cr in Mar 2021 to Rs 25.99 Cr in Mar 2025.
- −The company reported a net loss of Rs 2.57 Cr in Mar 2023.
- −No DII or FII holding was reported as of Mar 2026, indicating a lack of institutional investor interest (0% each).
- −Overall decrease in EPS from Rs 2.29 in Mar 2021 to Rs 1.40 in Mar 2025.
Financial Performance
Aashka Hospitals Limited reported revenue of Rs 25.99 Cr for the most recent fiscal year (Mar 2025). This follows revenues of Rs 27.09 Cr in Mar 2024, Rs 22.05 Cr in Mar 2023, Rs 39.86 Cr in Mar 2022, and Rs 40.69 Cr in Mar 2021. The company's net profit for Mar 2025 was Rs 3.27 Cr, compared to Rs 2.36 Cr in Mar 2024. The company experienced a net loss of Rs 2.57 Cr in Mar 2023.
Profitability & Returns
The company's Earnings Per Share (EPS) was Rs 1.40 in Mar 2025. This compares to an EPS of Rs 1.01 in Mar 2024 and an EPS of Rs -1.10 in Mar 2023. Prior to that, EPS was Rs 1.12 in Mar 2022 and Rs 2.29 in Mar 2021. The EBITDA for Mar 2025 was Rs 4.67 Cr.
Balance Sheet
Aashka Hospitals Limited has a debt-to-equity ratio of 0.17, indicating a relatively low level of debt in comparison to its equity. No other balance sheet figures like book value or comprehensive debt details were provided in the available data.
Ownership & Pledges
As of Mar 2026, promoters held 61.33% of the company's shares. Public shareholding stood at 38.67%. There was no reported pledge on promoter shares. Institutional holdings, including DII and FII, were 0%. The number of shareholders as of Mar 2026 was 1126.
Data as of — price: 2026-09-17 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.